Blood pressure after treatment with sodium–glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score‐matched models

Aims/Introduction Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve renal outcome in patients with type 2 diabetes mellitus, but the mechanism is not fully understood. The aim of this retrospective study was to assess the association of achieved blood pressure with renal outcomes in Japanes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Cutaneous Immunology and Allergy 2021-01, Vol.12 (1), p.74-81
Hauptverfasser: Kobayashi, Kazuo, Toyoda, Masao, Hatori, Nobuo, Furuki, Takayuki, Sakai, Hiroyuki, Umezono, Tomoya, Ito, Shun, Suzuki, Daisuke, Takeda, Hiroshi, Minagawa, Fuyuki, Degawa, Hisakazu, Yamamoto, Hareaki, Machimura, Hideo, Chin, Keiichi, Hishiki, Toshimasa, Takihata, Masahiro, Aoyama, Kouta, Umezawa, Shinichi, Minamisawa, Kohsuke, Aoyama, Togo, Hamada, Yoshiro, Suzuki, Yoshiro, Hayashi, Masahiro, Hatori, Yutaka, Sato, Kazuyoshi, Miyakawa, Masaaki, Tamura, Kouichi, Kanamori, Akira
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims/Introduction Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve renal outcome in patients with type 2 diabetes mellitus, but the mechanism is not fully understood. The aim of this retrospective study was to assess the association of achieved blood pressure with renal outcomes in Japanese type 2 diabetes mellitus patients with chronic kidney disease. Materials and Methods We assessed 624 Japanese type 2 diabetes mellitus patients with chronic kidney disease taking SGLT2i for >1 year. The patients were classified as those with post‐treatment mean arterial pressure (MAP) of ≥92 mmHg (n = 344) and those with MAP of
ISSN:2040-1116
2040-1124
DOI:10.1111/jdi.13318